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Background: As genome-wide approaches prove difficult with genetically heterogeneous orphan diseases, we
developed a new approach to identify candidate genes. We applied this to Emery-Dreifuss muscular dystro-
phy (EDMD), characterised by early onset contractures, slowly progressive muscular wasting, and life-threat-
ening heart conduction disturbances with wide intra- and inter-familial clinical variability. Roughly half of
EDMD patients are linked to six genes encoding nuclear envelope proteins, but the disease mechanism
remains unclear because the affected proteins function in both cell mechanics and genome regulation.
Methods: A primer library was generated to test for mutations in 301 genes from four categories: (I) all
known EDMD-linked genes; (II) genes mutated in related muscular dystrophies; (III) candidates generated
by exome sequencing in five families; (IV) functional candidates — other muscle nuclear envelope proteins
functioning in mechanical/genome processes affected in EDMD. This was used to sequence 56 unlinked
patients with EDMD-like phenotype.
Findings: Twenty-one patients could be clearly assigned: 18 with mutations in genes of similar muscular dys-
trophies; 3 with previously missed mutations in EDMD-linked genes. The other categories yielded novel can-
didate genes, most encoding nuclear envelope proteins with functions in gene regulation.
Interpretation: Our multi-pronged approach identified new disease alleles and many new candidate EDMD
genes. Their known functions strongly argue the EDMD pathomechanism is from altered gene regulation and
mechanotransduction due to connectivity of candidates from the nuclear envelope to the plasma membrane.
This approach highlights the value of testing for related diseases using primer libraries and may be applied
for other genetically heterogeneous orphan diseases.
Funding: The Wellcome Trust, Muscular Dystrophy UK, Medical Research Council, European Community’s
Seventh Framework Programme “Integrated European omics research project for diagnosis and therapy in
rare neuromuscular and neurodegenerative diseases (NEUROMICS)”.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license.
(http://creativecommons.org/licenses/by/4.0/)Keywords:
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Orphan diseasehe Wellcome Centre for Cell
chael Swann Building, Room
V. This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)1. Introduction
Emery-Dreifussmuscular dystrophy (EDMD) is a rare neuromuscular
disorder affecting ~0.30.4 in 100,000 people [1,2]. EDMD patients
present typically in childhood with early contractures of elbows and
Achilles’ tendons, progressive wasting of lower leg and upper arm
Research in context
Evidence before this study
Emery-Dreifuss muscular dystrophy (EDMD) is a genetically het-
erogeneous orphan disease with clinical variability presenting
even in family members carrying the same mutation. The lack of
large pedigrees in combination with its genetic heterogeneity
(~50% of patients are solved with mutations in 6 genes), clinical
variability, several known modifier genes, limited patient num-
bers, and an unsolved pathomechanism make the usage of
genome-wide association sequencing studies ineffective. EDMD
also presents a conundrum in that all previously known alleles are
widely expressed nuclear envelope (NE) proteins, so how amuscle
focused pathology is achieved remains obscure. Moreover the pro-
teins involved have known functions in nuclear/cellular mechani-
cal stability, genome regulation, and cell cycle regulation, so that
the EDMD pathomechanism remains unclear.
Added value of this study
The new fully solved and candidate alleles encode proteins that
form a physical connection from the plasma membrane to the
nuclear envelope, further elaborating genome regulation and
mechanosignal transduction as the pathomechanism and sup-
porting the validity of new candidates. This connectivity
together with that several of the new candidate alleles are mus-
cle-specific resolves the conundrum of how a muscle-focused
pathology could come from widely-expressed proteins. The
range of proteins that can be disrupted through these connec-
tions moreover can help explain the clinical variability and also
the overlaps to similar muscular dystrophies. Notably, the
larger set of candidates from the exome sequencing step in our
approach likely contains also modifying alleles that may be
revealed with further use of the primer library.
Implications of all the available evidence
If this patient cohort is representative of the general patient popu-
lation this approach likely solves >90% of the ~50% remaining
genetically unsolved patients, and in doing so strongly implicates
altered gene regulation and mechanotransduction as its pathome-
chanism. Furthermore, in addition to the potential application of
this approach to other genetically heterogeneous orphan diseases,
the primer library once generated provides a better and cheaper
sequencing strategy for newly diagnosed patients compared to
traditional Sanger sequencing of one linked gene at a time. The
EDMD patient association has noted a problem with the time
from clinical presentation to diagnosis that will be resolved with
the wider application of this primer library and allow earlier inter-
ventions to improve disease management.
2 P. Meinke et al. / EBioMedicine 51 (2020) 102587muscles, and later development of cardiac conduction defects and, in a
proportion of cases, dilated cardiomyopathy [3]. Features vary consider-
ably in clinical presentation, leading to the usage 'Emery-Dreifuss-like
syndromes' [4,5]: patients from the same pedigree can show remark-
able phenotypic variation [6]. Consistent with this variation, EDMD is
also genetically variable: ~half of EmeryDreifuss-like syndrome cases
are linked to mutations in genes encoding 6 nuclear envelope proteins
(emerin, lamin A, nesprin 1, nesprin 2, SUN1 and FHL1 [711]). Variants
in desmin and the nuclear envelope proteins SUN1 and SUN2 have been
reported to modify the EDMD phenotype [10,12]. Roughly half of clini-
cally diagnosed patients remain unlinked [13].The strong nuclear envelope link raised the possibility that remain-
ing unlinked patients might also have mutations in nuclear envelope
proteins. The nuclear envelope is linked to >30 inherited diseases and
syndromes [14], each with distinct tissue-specific pathologies: for
example different lamin A mutations cause muscular dystrophies, neu-
ropathy, lipodystrophy, and multisystemic disorders. How these widely
expressed nuclear envelope proteins yield tissue-specific pathologies
remains unresolved, but one hypothesis is that tissue-specific nuclear
envelope partners mediate the tissue-specificity of effects [15].
We previously identified several muscle-specific nuclear envelope
transmembrane proteins (NETs) [16]. Of the previously linked proteins
emerin, nesprin 1, nesprin 2, SUN1, SUN2, and Tmem43 are all NETs, but
these are widely expressed. Several of themuscle-specific NETs identified
could contributemuscle specificity to either of the two principly hypothe-
sized EDMD pathomechanisms: mechanical instability and disruption of
gene expression. NETs Tmem214 and KLHL31 track with microtubules
on the nuclear surface [16] while NET5/Samp1 contributes actin and cen-
trosome interactions [17]. NETs Tmem38A, WFS1, NET39/PLPP7 and,
again, Tmem214 and NET5/Samp1 all affect 3D gene positioning with
corresponding effects on gene expression [18,19]. Many of the genes
under muscle-specific NET regulation are recruited to the nuclear periph-
ery to bemore tightly shut down duringmyogenesis and encode proteins
that are antagonistic to myogenesis or are from alternative differentiation
pathways such as adipogenesis. Knockdown of the muscle-specific NETs
results in these genes being de-repressed, suggesting a possible genemis-
regulation mechanism to disease pathology. The potential of gene mispo-
sitioning contributing to disease is further underscored by knockdown of
Tmem38A, WFS1, and NET39/PLPP7 blocking myotube fusion [18]. Func-
tional overlap of these muscle-specific NETs supports the possibility of
their working in a common pathway towards EDMD pathophysiology,
making them good candidates for mediators of EDMD muscle pathology
at the same time as being novel candidates for causative EDMD alleles.
Therefore, we elected to sequence the genes encoding these muscle-
specific NETs in unlinked EDMD patients using a primer library. How-
ever, for greater surety, we expanded this primer library to also re-check
previously linked genes with complete gene sequencing for possible
promoter mutations and to test for mutations in genes linked to related
muscular dystrophies. Finally, to also search for candidate alleles in a
completely unbiasedmanner, we performed exome sequencing in fami-
lies for which material from enough members was available for linkage
analysis and added these candidates also to the primer library (Fig. 1a).
2. Materials and methods
2.1. Patient materials
All patient DNA used for sequencing was obtained from blood
samples. RNA was obtained from deltoid muscle from the family 1
index patient and matching control. The sources of patient samples
were: the Muscle Tissue Culture Collection (MTCC) at the Friedrich-
Baur-Institut (Department of Neurology, Ludwig-Maximilians-Uni-
versity, Munich, Germany); the Institute of Human Genetics, Univer-
sity of Newcastle upon Tyne, Newcastle upon Tyne, UK; the MRC
Centre for Neuromuscular Disorders Biobank (CNDB) in London; the
Department of pediatric Neurology, Developmental Neurology and
Social Pediatrics at the University of Essen; the Rare Diseases biologi-
cal samples biobank at the Dubowitz Neuromuscular Centre, Great
Ormond Street Hospital for Children NHS Trust, London, UK.
2.2. Ethical approval and consent to participate
All materials were obtained with written informed consent of the
donor at the CIND, the CNDB or the MTCC. Ethical approval for the New-
castle MRC Centre Biobank for Neuromuscular Diseases is covered by
REC reference 08/H0906/28+5 and IRAS ID 118,436 and MTA CT-2166,
that of the Rare Diseases biological samples biobank for research to
Fig. 1. Methodology and top candidate mutations from exome sequencing. (a) Flow chart describing the study methodology. (b) Pedigrees of the 5 families used for the initial
exome sequencing with top candidate mutations listed in the adjacent boxes (MAF = minor allele frequency). The presented top candidate mutations were identified in all
sequenced affected family members, but not in unaffected family members. Sequenced individuals: yellow; males: square; females: circles; patients: filled black. The presented top
candidate mutations were identified in all sequenced affected family members, but not in unaffected family members.
P. Meinke et al. / EBioMedicine 51 (2020) 102587 3facilitate pharmacological, gene and cell therapy trials in neuromuscular
disorders is covered by REC reference 06/Q0406/33 with MTA reference
CNMDBBL63 CT-2925/CT-1402, and for this particular study was
obtained from the West of Scotland Research Ethics Service (WoSRES)
with REC reference 15/WS/0069 and IRAS project ID 177,946.
2.3. Exome, RNA, and genome sequencing
Genome: 15X clean depth coverage using 90PE Illumina
HiSeq2000 technology. RNA-Seq: total RNA from biopsy tissue with
rRNA depletion and random-primed cDNA preparation and PE100
sequencing on a Hi-Seq2000 platform with 20 million reads mini-
mum (Otogenetics Corporation, Norcoss, USA).
Exome: Sequencing was performed on the Illumina HiSeq and raw
data processed with CASAVA 1.8.
2.4. Fluorescence in situ hybridisation
Mutations were generated by Agilent Site-Directed mutagenesis.
Plasmids encoding tagged Tmem38a, PLPP7 and mutants were trans-
fected using Lipofectamine 3000 (Invitrogen) into C2C12 cells (ATCC,VA, USA) cultured at 37 °C, 5% CO2 in DMEM containing 20% FBS, 50 U/
mL penicillin and 10 mg/mL streptomycin. Fluorescent in situ hybrid-
isation (FISH) experiments were performed as described in [20].
2.5. Primer library construction, processing and sequencing
A SureSelectXT Custom 1.638 Mbp target enrichment library
(51904817) containing 25,036 oligonucleotide probes against H.
sapiens hg19 GRCh37 sequence as of February 2009 was prepared by
Agilent for use with Illumina multiplexed sequencing platforms.
Patient genomic DNA was isolated from blood and prepared for
sequencing using the SureSelectQXT Reagent Kit (G9681B) according
to the manufacturer’s instructions. Recommended minimum
sequencing per sample was 327.793 Mbp and an average of 3427,092
was obtained with a range from 442,125 to 7066,507 using 125 base
paired-end sequencing on a Hi-Seq2500.
2.6. Bioinformatics and analysis
Variant analysis was performed using the Genome Analysis toolkit
[GATK] v2.72 [21] and picard tools v1.74 (http://broadinstitute.
Fig. 2. Primer library composition and gene ontology (GO) functions/localisations of all candidate genes from the four categories contributing to the primer library construction and
for the top candidates identified after primer library sequencing. (a) Composition of the primer library with number of genes from each of the four categories used in its construction
(upper panel) and number of patients solved/with likely candidates from the different categories after primer library sequencing (lower panel). (b) Presence in muscle nuclear enve-
lopes for the starting library in comparison to the overall genome (upper panel) and of the remaining candidate genes after primer library sequencing (lower panel) in percent
(based on GO-localisation terms and/or experimental evidence from appearance in nuclear envelope proteomics datasets20,28). (c) GO-terms for genome organisation, cytoskeleton,
and genome organisation and cytoskeleton combined functions involvement for the starting library in comparison to the overall genome (upper panel) and of the remaining
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[22,23] against human genome assembly hg19. The allele frequencies
of variants were cross-referenced with gnomAD version 2.1 [24]
using both the genome and exome datasets.
RNA-Seq: STAR v2.1.1 [25] was used to map reads to the hg19 ref-
erence genome, samtools v0.1.19 [26] was used for file conversion.
Deeptools v1.5.1 [27] was used for downstream analysis.
3. Results
3.1. Sequencing EDMD families
Whole exome sequencing was performed in 12 EDMD patients
and 12 unaffected individuals from 5 families with large enough ped-
igrees for linkage analysis (Fig. 1b), finding over 250,000 variants
compared to the reference sequence. Variants were filtered using cri-
teria: (a) phenotype co-segregation and modes of inheritance for
each family; (b) selecting for SNP frequencies <1%, and filtering for
<0.05%; (c) affecting coding sequence; (d) function/tissue-expression
of the encoded protein e.g. >2-fold higher expression in muscle com-
pared to other tissues. Filtering yielded 213 candidate genes for fami-
lies 25 (Supplemental Table S1).
Family 1 yielded no convincing candidates. As this family had the
largest pedigree, we postulated that an unaffected individual was a
carrier who had not yet presented or had a distinct sporadic form of
disease. Dropping younger individuals who may have not yet pre-
sented clinically failed to yield candidates; therefore, genome and
transcriptome sequencing was performed on the index patient,
resulting in 33 additional candidates (Supplemental Tables S2 and
S3). The combined exome, genome and RNA sequencing yielded a
total of 252 candidates from the five families.
3.2. Primer library sequencing
A primer library was generated containing (I) the 8 previously-
linked EDMD gene ORFs plus the whole genes for LMNA and EMD (that
together account for ~40% of linked alleles), (II) 25 genes from similar
muscular dystrophies, (III) the 252 exome sequencing candidates, and
(IV) 16 functional candidates, mostly muscle-specific nuclear envelope
proteins (Fig. 2a; Supplemental Table S4). Sequencing was performed
on 56 additional unlinked clinically diagnosed EDMD patients unre-
lated to each other, obtaining on average 3427,092 reads per patient.
The data were analysed for genes carrying mutations that changed the
coding sequence (nonsense, missense, splice sites) with expected
altered protein function (e.g. non-conservative substitutions) and SNP
frequencies<0.05% (Supplemental Table S5).
Candidate mutations were found in all four categories. Of category
I previous EDMD-linked genes, LMNA had mutations in three patients
that were missed in standard diagnostics (p.R41H, p.R249Q, p.
G535fs*; Table 1). These mutations were determined as causative
based on similarity to previously linked LMNA mutations. Previously
EDMD-associated genes SYNE1, SYNE2, SUN1 and TMEM43 also had
mutations; however, minor allele frequencies and their combination
with other mutations made them unlikely as causative alleles except-
ing SYNE1. Modifying effects, nonetheless, cannot be excluded. No
mutations were found in LMNA or EMD non-coding regions.
Gene category II of related muscular dystrophies yielded 18
patients with mutations considered causative. Four of these patients
had combinations of a missense and frameshift mutation in CAPN3
(Table 1). GBE1 mutations were found in four other patients: threecandidate genes after primer library sequencing (lower panel) in percent, showing an enrich
remaining candidate genes after library sequencing based on STRING (Search Tool for the R
dence) showing that most candidates are linked to other candidates and that these form co
consistent with possible mechanotransduction from the extracellular region to the nuclear e
proteins are displayed by colour-coding (based on GO-terms and/or experimental evidence tmissense and one splice-site. VCP and likely recessive TTN were
mutated in two patients each; however, TTN mutation patients also
carried SYNE1 mutations. Genes with one patient carrying likely dis-
ease-causing mutations were COL6A1, CAV3, DMD, ANO5, DYSF and
POMT1. The DMD mutation created a stop codon at codon three,
resulting in possible usage of an alternative start codon and a milder
phenotype than Duchenne [28]. For ANO5, DYSF and POMT1 the
respective patients had two mutations, consistent with the reported
inheritance (autosomal recessive for MD-20/ANO5 and unknown for
MD-21/DYSF and MD-23/POMT1; Table 1). However, lacking DNA
from the parents we could not perform segregation studies.
Category III genes from exome sequencing were elevated to
"likely-causative" candidates if also mutated in multiple patients
within the primer library cohort based on the assumption that causa-
tive genes will be independently mutated in multiple patients. The
top candidates were INTS1, ANK2, XIRP1 and USP34. Heterozygous
ANK2 mutations were identified in family 5 plus six cohort patients
with no other obvious disease-causing mutations and so were most
likely causative (Table 2). Causation is similarly likely for other genes;
however, in some patients there were additional candidate alleles
identified. Heterozygous INTS1 was mutated in four members of fam-
ily 3 plus five cohort patients, four of whom had no mutation in
already associated genes (Table 2). The last patient, MD-23, addition-
ally carried two POMT1 mutations; however, it is unclear if the likely
recessive POMT1 mutations affected one allele or both so causation
remains undetermined. Other good category IV candidates were
USP34 (heterozygous mutations in exome sequenced family 2) and
XIRP1 (mutated in families 2 and 4), each with mutations in an addi-
tional five patients. Some patients had additional mutations in
already associated genes, but if these other mutations were causative
then modifying effects for the new candidates are still possible.
Several category IV functional/tissue candidate genes were
mutated in 16 of the 56 primer library cohort patients. These were
WFS1 (4 patients), TMEM201 (3 patients), TMEM38A (3 patients),
PLPP7 (2 patients), TMEM214 (2 patients), LPCAT3 (1 patient), KLHL31
(1 patient), and BVES (1 patient). Of these, three patients with
TMEM38A mutations, two patients with TMEM214 mutations, one
patient with an LPCAT3 mutation and one patient with a BVES muta-
tion were clearly the top candidates with no other reasonable candi-
dates identified and patient MD-32 carried mutations in both
TMEM38A and PLPP7. Other mutations identified were in association
with other possible candidates that included likely causative muta-
tions in GBE1, COL6A1, LMNA and TTN (details in Table 1). The patient
with the combined LMNA and TMEM201 mutations had a very early
age of onset (1 year), suggesting that both mutations contribute to
the more severe (congenital) phenotype as the LMNA mutation has
not been associated with congenital muscular dystrophy.
All in all, sequencing the 56 additional patients with the primer
library found mutations in only a subset of the 252 candidates from
the exome sequencing and this subset is expected to be much higher
confidence because causative genes are more likely to be also
mutated in other EDMD patients. In contrast, mutations were found
in 19 of 25 related muscular dystrophies and in 11 of 16 functional
candidates; so a strong enrichment for these candidate pools was
observed (Fig. 2a).
3.3. Nuclear envelope links
All previously linked EDMD genes encode nuclear envelope pro-
teins. The functional candidates were also biased towards genesment for the combined category in the top candidate alleles. (d) Interactive network of
etrieval of Interacting Genes/Proteins, https://string-db.org/) interactions (high confi-
nnections from the nuclear envelope to the plasma membrane. These connections are
nvelope being the core disrupted function in EDMD. Different described localisations of
hrough identification in muscle nuclear envelope proteomics datasets20).
Table 1
Solved Patients.
(continued)
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Dark green: known disease associated genes (EDMD or similar MDs) with likely disease causing mutation (category 2 and 3).
Light green: known disease associated genes (EDMD or similar MDs) with unlikely disease causing mutation or two genes of similar likelihood to be the causative disease allele (cat-
egory 2 and 3).
Yellow: functional candidate gene mutations (category 1).
Purple: mutations in genes from the family sequencing (category 4).
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Patients with Candidate Genes.
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Light green: known disease associated genes (EDMD or similar MDs) with unlikely disease causing mutation or two genes of similar likelihood to be the causative disease allele (cat-
egory 2 and 3).
Yellow: functional candidate gene mutations (category 1).
Purple: mutations in genes from the family sequencing (category 4).
P. Meinke et al. / EBioMedicine 51 (2020) 102587 17identified in the nuclear envelope by proteomics; however, there was
no bias towards the nuclear envelope when selecting genes for the
primer library from similar muscular dystrophies or from exome
sequencing. Nonetheless, the majority of genes from similar muscular
dystrophies encode proteins for which at least a subpopulation asso-
ciates with the nuclear envelope (Fig. 2b). Interestingly, just consider-
ing the candidates from the exome sequencing in which mutations
were also found in other patients from the primer library sequencing,
the nuclear envelope portion increased from less than 10% to more
than 40% - considerably more than the overall genome portion of
5.9% (Fig. 2b). Of note, the proteins encoded by genes linked to other
muscular dystrophies such as COL6A1, CAV3, DYSF, DMD, TTN, and
VCP and the strongest family sequencing candidates INTS1 and ANK2
were all found in nuclear envelope proteomics datasets [16,29].
While these could reflect either a separate pool in the nuclear enve-
lope or connections that were maintained during nuclear envelope
isolation, this suggests at least an indirect physical connection of
these candidates to the nuclear envelope.
The two top argued mechanisms for how mutations in nuclear
envelope proteins can cause pathology are mechanical instability and
genome misregulation. Genes in different candidate categories con-
tained Gene Ontology (GO)-terms for functions in gene regulation,
cytoskeleton, and both together. Interestingly, the likely candidates
from all categories were enriched for genes simultaneously linked to
both gene regulation and cytoskeleton GO-terms compared to the
overall genome (Fig. 2c). Such genes may be involved in mechanosig-
nal transduction to the genome. Consistent with this idea, most ofthe proteins encoded by the final candidate genes interact with other
candidates according to interactome studies and these interactions
form a chain of connectivity between the nuclear envelope and the
plasma membrane via cytoskeletal proteins that could support
mechanotransduction to the genome (Fig. 2d).
3.4. Confirmation of novel EDMD alleles
Thus far only the three LMNA mutations, the CAV3 and one of the
CAPN3 (MD-43) mutations have been fully confirmed as insufficient
numbers of family members have come to clinic for linkage analysis.
Therefore, to test the likelihood that other mutations identified cause
EDMD disease pathology, we tested two of the gene regulating NETs
to determine if the mutations identified disrupt their normal func-
tions in myogenic gene regulation. In keeping with this idea, for the 8
out of 16 functional NET candidates where mutations were found (6
of which have known gene regulation functions), nearly all mutations
identified faced the nucleoplasm or were positioned where they
could alter membrane topology (Fig. 3a). The two muscle-specific
NETs we chose to test were PLPP7/NET39 and Tmem38A. Both recruit
largely non-overlapping sets of genes to the nuclear periphery to
enhance their repression and many of the genes targeted are antago-
nistic to myogenesis or from alternate (non-muscle) differentiation
pathways [18]. Combined knockdown of PLPP7/NET39, TMEM38A
and WFS1 blocked myogenesis, providing a logical route from their
disruption to muscle disease pathology. Therefore, the PLPP7 and
TMEM38Amutations were exogenously expressed in C2C12 myoblast
Fig. 3. Mutations in muscle gene-repositioning NETs affect their ability to recruit genes to the nuclear envelope (NE). (a) Schematic presentation of the topology of further muscle
NETs and their mutations identified by the primer library sequencing. The lipid bilayers of the nuclear envelope are shown in dark grey and the lumen of the nuclear envelope in
light grey. Transmembrane segments are thicker black rectangles and point mutations identified are shown in blue. The mutations identified are all positioned in nucleoplasmic
regions where they could either interact with the genome or at transmembrane spans where they could disrupt protein topology and hence also genome interactions. (b) FISH
showing the localisation of the DDR2 gene (green) in C2C12 mouse myoblasts upon the expression of RFP-tagged wild type and mutant TMEM38A that can be seen in both cases to
target to the nuclear envelope (red, upper panel). The cumulative frequency of the distance of the gene loci to the NE for each mutation compared to the wild type is shown under
each image of the cells expressing the mutant NETs and a whisker plot summary for the distance to the NE of all mutations is given in the lower left corner. Both mutations block
the ability of TMEM38A to reposition the DDR2 locus to the NE. (c) FISH showing the localisation of the PTN gene (green) in C2C12 mouse myoblasts upon the expression of GFP-
tagged wild type and mutant PLPP7 (red, upper panel). Cumulative frequency plots of the distance of the gene loci to the NE for each mutation and the summary for the distance to
the NE of all mutations are given as in B. The mutations also affect the gene repositioning function of PLPP7. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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P. Meinke et al. / EBioMedicine 51 (2020) 102587 19cells to determine if they could perform the previously shown gene
positioning function of the wild-type in recruiting specific gene tar-
gets to the nuclear periphery for enhanced repression. Tmem38A
normally repositions the DDR2 gene locus to the nuclear envelope to
repress it during myogenesis, but with mutations p.N260D and p.
N260del it fails to do so (Fig. 3b). Similarly, PLPP7/NET39 normally
recruits the PTN gene locus to the nuclear envelope to repress it dur-
ing myogenesis, but with mutation p.R252P it could not. PLPP7/
NET39 mutation p.M92K also affected the gene positioning, though
apparently in the opposite direction which might also affect expres-
sion (Fig. 3c). Testing effects of both PLPP7 and TMEM38A mutations
on nuclear morphology [30] did show that only TMEM38A p.N260D
had a slight increase in numbers of abnormally shaped nuclei (Sup-
plementary Fig. 1).4. Discussion
Failure of high throughput genomic approaches to identify new
disease alleles can at least in some cases be overcome by our multi-
stage approach. This approach pinpointed candidates in part based
on the preferential tissue focus of pathology and in part on the sub-
cellular localisation of known alleles. Similarly applying filters in
focusing candidates for such a multipronged approach can be applied
to other genetically heterogeneous diseases.
With nearly half of EDMD cases previously linked to genes encod-
ing 6 nuclear envelope proteins it was clear that EDMD is a nuclear
envelope disease. This is strengthened by enrichment for nuclear
envelope proteins amongst our top new candidate alleles. COL6A1,
CAV3, DYSF, DMD, TTN, and VCP gene products were found in muscle
nuclear envelopes [16]. As most of these proteins have previously
been associated with the cytoskeleton or plasma membrane, their
association with the nuclear envelope may be indirect through
lamin-cytoskeletal connections. However, this association could also
be due to splice variants that target to the nuclear envelope or spe-
cific translocation to the nucleus under certain conditions as has
been shown for CAV3 family member caveolin 2. In this case, a caveo-
lin 2 subpopulation translocates to the nucleus and interacts with
lamin A to regulate histone modifications and gene expression [31].
The gene positioning defects for TMEM38A and PLPP7 mutations
not only further link the nuclear envelope to EDMD, but also
strengthen the idea that misregulation of myogenic gene expression
is the primary cause of EDMD pathology. In addition to Tmem38A
and Plpp7, the muscle NETs Tmem214, WFS1, and NET5/Samp1 all
have gene-repositioning functions that contribute to gene regulation
and the NET MAN1 affects gene regulation through its interactions
with Smads as well as binding several chromatin partners [32]. The
involvement of these muscle gene repositioning NETs, not only as
novel causative alleles but also in mediating EDMD pathology caused
by mutations in widely expressed nuclear envelope proteins, is fur-
ther supported by WFS1, Tmem214, Tmem38A, and NET5/Samp1
being mislocalised in isolated differentiating EDMD muscle cells or
muscle biopsy sections [33].
Of the previously EDMD-linked nuclear envelope proteins, Lamin
A has both cytoskeletal and genome regulation functions; so its
mutation could support both mechanical instability and genome mis-
regulation hypotheses for EDMD pathophysiology [3437]. Emerin
interacts with actin supporting a cytoskeletal role, but it also has
many reported contributions to genome regulation through its bind-
ing DNA condensing factors BAF and HDAC3, splicing factors, the
transcription factor Lmo7, and the transcriptional repressor germ
cell-less [38]. FLH1 is linked to signal transduction and splice variant
FHL1B targets specifically to the nuclear envelope [39]. Moreover,
FHL1 has been linked to other myopathies such as X-linked myopa-
thy with postural muscle atrophy (XMPMA) [40] via its signal trans-
duction function.As signalling functions could affect both gene regulation and the
cytoskeleton, these mechanisms toward pathology were considered
equally likely; however, a gene mis-regulation mechanism is much
more likely now with the new gene-repositioning candidate alleles
identified. Though there are some other disparate functions reported
for several of these NETs [16,41,42], WFS1, Tmem38A/TRIC-A, NET39/
PLPP7, Tmem214 and NET5/Samp1 are all at the nuclear envelope
preferentially in muscle and all share a common function in directing
gene-repositioning for regulation of gene expression during myogene-
sis [18]. That some of these muscle-specific NETs had overlap in their
functions further supports the possibility of their working in a com-
mon pathway towards EDMD pathophysiology. Interestingly,
Tmem214 regulated genes exhibited considerable overlap with WFS1,
Tmem38A, and NET39 regulated genes, suggesting it functions in
mechanosignal transduction, while the others each had principally
unique gene targets. The links of candidate alleles to gene misregula-
tion are the more compelling in this context because the different sets
of genes regulated by WFS1, Tmem38A, and NET39 — all important in
myogenesis— thus support the clinical variation observed in EDMD.
Our sequencing in patients diagnosed with an EDMD-like pheno-
type identified mutations in several genes linked to muscular dystro-
phies that share clinical features with EDMD. This might reflect
incorrect diagnoses or their involvement in EDMD. The latter case
seems likely, considering that COL6A1, CAV3, DYSF, DMD, TTN, and VCP
gene products link to the nuclear envelope. Indeed, many of these
gene products interact with one another in a way that could form a
chain from the plasma membrane to the nuclear envelope (Fig. 2d).
This also is compelling for the gene regulation pathomechanism as
this chain could enable mechanosignal transduction to the nucleus.
Finally, as the families chosen for exome sequencing all had differ-
ences in presentation, there are likely additional mutations picked up
in the primer library that may be disease modifiers and so might
eventually be used as predictors of severity or other aspects of pre-
sentation such as cardiac involvement once further sequencing
reveals better correlations. Thus it would be beneficial to continue
using this primer library diagnostically both to find these correlations
and because it is cheaper and faster than standard iterative Sanger
sequencing for such a genetically variable disease to identify muta-
tions in known linked genes. In general, this iterative multipronged
approach, combining into a primer library a set of preliminary candi-
dates from exome sequencing in which only sufficient pedigrees exist
for partial linkage analysis together with candidates from related dis-
orders and candidates specific to the tissue where pathology is mani-
fested that are associated with linked organelles and functions, might
be applied to a wider range of genetically heterogeneous orphan dis-
eases where insufficient numbers of patients are available for stan-
dard genome and exome approaches to be effective. A further benefit
of this primer library is the possibility to add additional genes at a
later time point. This might become necessary when a better under-
standing of EDMD identifies more causative or modifying genes
involved in the disease pathology.
Funding sources
Funding for this work was principally provided byWellcome Trust
Grants 095209, Muscular Dystrophy UK grant 18GRO-PG24-0248,
and MRC grant MR/R018073/1 to ECS and 092076 for the Centre for
Cell Biology. Funding was also provided by the European Commun-
ity’s Seventh Framework Programme (FP7/2007-2013) “Integrated
European omics research project for diagnosis and therapy in rare
neuromuscular and neurodegenerative diseases (NEUROMICS)”
(grant agreement no. 2012-305121); the Muscular Dystrophy UK
Grant on Gene Identification to FM, and the support of the MRC Neu-
romuscular Centre Biobank at UCL is also gratefully acknowledged.
The funders played no role in study design, data collection, data anal-
ysis, interpretation, and writing of the report.
20 P. Meinke et al. / EBioMedicine 51 (2020) 102587Declaration of Competing Interest
Dr. Meinke reports personal fees from Greenovation Biopharma-
ceuticals, outside the submitted work; Dr. Harris reports grants from
Muscular Dystrophy-UK, during the conduct of the study; Dr. Koelbel
reports personal fees from Santhera, personal fees from Sarepta, per-
sonal fees from Biogen, personal fees from Avexis, outside the submit-
ted work; Dr Schara reports personal fees for consulting from Alexion,
Santhera, PTC, Ipsen, Biogen, Sarepta, Dynacure, Novartis, Avexis and
Sanofi; Dr. Muntoni reports personal fees from Pfizer, personal fees
from Roche, personal fees from Biogen, personal fees from Avexis, per-
sonal fees from Sarepta, grants from Sarepta, outside the submitted
work; Dr. Schoser reports Advisory boards: Amicus Therapeutics,
Audentes Therapeutics, Nexien Biopharm, Lupin therapeutics, Sanofi
Genzyme. Contracted research: Amicus therapeutics, Greenovation
Biopharm, Sanofi Genzyme. Honoraria: Kedrion. Travel expenses:
Sanofi Genzyme. Dr. Kerr, Dr. Czapiewski, Dr. de las Heras, Mr. Dixon,
Dr. Straub, Dr. Wehnert and Dr. Schirmer have nothing to disclose.
Acknowledgements
We dedicate this study in honour of Alan E.H. Emery who not only
described X-linked EDMD as a distinct disease in 1966 but also
helped instigate the longest standing regular Laminopathy meeting
in 2006. We further want to thank all patients and their families for
their valuable contribution.
Supplementary materials
Supplementary material associated with this article can be found
in the online version at doi:10.1016/j.ebiom.2019.11.048.
References
[1] Hughes MI, Hicks EM, Nevin NC, Patterson VH. The prevalence of inherited neuro-
muscular disease in Northern Ireland. Neuromuscul Disord 1996;6(1):69–73.
[2] Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of
genetic muscle disease in Northern England: in-depth analysis of a muscle clinic
population. Brain 2009;132(11):3175–86.
[3] Emery AE, Dreifuss FE. Unusual type of benign x-linked muscular dystrophy. J
Neurol Neurosurg Psychiatry 1966;29(4):338–42.
[4] Emery AE. Emery-Dreifuss syndrome. J Med Genet 1989;26(10):637–41 [Review].
[5] Knoblauch H, Geier C, Adams S, Budde B, Rudolph A, Zacharias U, et al. Contrac-
tures and hypertrophic cardiomyopathy in a novel FHL1 mutation. Ann Neurol
2010;67(1):136–40.
[6] Bonne G, Mercuri E, Muchir A, Urtizberea A, Becane HM, Recan D, et al. Clinical
and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscu-
lar dystrophy due to mutations of the lamin A/C gene. Ann Neurol 2000;48
(2):170–80.
[7] Bione S, Maestrini E, Rivella S, Mancini M, Regis S, Romeo G, et al. Identification of
a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat
Genet 1994;8(4):323–7.
[8] Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, Merlini L, et al.
Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-
Dreifuss muscular dystrophy. Nat Genet 1999;21(3):285–8.
[9] Zhang Q, Bethmann C, Worth NF, Davies JD, Wasner C, Feuer A, et al. Nesprin-1
and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy
and are critical for nuclear envelope integrity. Hum Mol Genet 2007;16
(23):2816–33.
[10] Meinke P, Mattioli E, Haque F, Antoku S, Columbaro M, Straatman KR, et al. Mus-
cular dystrophy-associated SUN1 and SUN2 variants disrupt nuclear-cytoskeletal
connections and myonuclear organization. PLoS Genet 2014;10(9):e1004605.
[11] Gueneau L, Bertrand AT, Jais JP, Salih MA, Stojkovic T, Wehnert M, et al. Mutations
of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Am J Hum Genet
2009;85(3):338–53.
[12] Muntoni F, Bonne G, Goldfarb LG, Mercuri E, Piercy RJ, Burke M, et al. Disease
severity in dominant Emery Dreifuss is increased by mutations in both emerin
and desmin proteins. Brain 2006;129(5):1260–8.
[13] Meinke P. Molecular genetics of EmeryDreifuss muscular dystrophy. Chichester:
JohnWiley & Sons, Ltd; 2018.
[14] Meinke P, Schirmer EC. The increasing relevance of nuclear envelope myopathies.
Curr Opin Neurol 2016;29(5):651–61.[15] Wilkie GS, Schirmer EC. Guilt by association: the nuclear envelope proteome and
disease. Mol Cell Proteomics 2006;5(10):1865–75.
[16] Wilkie GS, Korfali N, Swanson SK, Malik P, Srsen V, Batrakou DG, et al. Several
novel nuclear envelope transmembrane proteins identified in skeletal muscle
have cytoskeletal associations. Mol Cell Proteomics 2011;10(1) M110 003129.
[17] Osorio DS, Gomes ER. Connecting the nucleus to the cytoskeleton for nuclear
positioning and cell migration. Adv Exp Med Biol 2014;773:505–20.
[18] Robson MI, de Las Heras JI, Czapiewski R, Le Thanh P, Booth DG, Kelly DA, et al.
Tissue-Specific gene repositioning by muscle nuclear membrane proteins enhan-
ces repression of critical developmental genes during myogenesis. Mol Cell
2016;62(6):834–47.
[19] Zuleger N, Boyle S, Kelly DA, de las Heras JI, Lazou V, Korfali N, et al. Specific nuclear
envelope transmembrane proteins can promote the location of chromosomes to
and from the nuclear periphery. Genome Biol 2013 15;14(2):R14.
[20] Zuleger N, Boyle S, Kelly DA, de las Heras JI, Lazou V, Korfali N, et al. Specific
nuclear envelope transmembrane proteins can promote the location of chromo-
somes to and from the nuclear periphery. Genome Biol 2013;14(2):2013–4.
[21] McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The
genome analysis toolkit: a mapreduce framework for analyzing next-generation
DNA sequencing data. Genome Res 2010;20(9):1297–303.
[22] DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A frame-
work for variation discovery and genotyping using next-generation DNA
sequencing data. Nat Genet 2011;43(5):491–8.
[23] Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine
A, et al. From FastQ data to high confidence variant calls: the genome analysis
toolkit best practices pipeline. Curr Protoc Bioinformatics 2013;43 11 0 1-33.
[24] Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf€oldi J, Wang Q, et al. Varia-
tion across 141,456 human exomes and genomes reveals the spectrum of loss-of-
function intolerance across human protein-coding genes. bioRxiv. 2019:531210.
[25] Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast
universal RNA-seq aligner. Bioinformatics 2013;29(1):15–21.
[26] Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence
alignment/map format and SAMtools. Bioinformatics 2009;25(16):2078–9.
[27] Ramirez F, Dundar F, Diehl S, Gruning BA, Manke T. deepTools: a flexible platform
for exploring deep-sequencing data. Nucleic Acids Res 2014;42:W187–91.
[28] Flanigan KM, von Niederhausern A, Dunn DM, Alder J, Mendell JR, Weiss RB. Rapid
direct sequence analysis of the dystrophin gene. Am J Hum Genet 2003;72
(4):931–9.
[29] Korfali N, Wilkie GS, Swanson SK, Srsen V, de Las Heras J, Batrakou DG, et al. The
nuclear envelope proteome differs notably between tissues. Nucleus 2012;3
(6):552–64.
[30] Filippi-Chiela EC, Oliveira MM, Jurkovski B, Callegari-Jacques SM, da Silva VD,
Lenz G. Nuclear morphometric analysis (NMA): screening of senescence, apopto-
sis and nuclear irregularities. PLoS ONE 2012;7(8):e42522.
[31] Jeong K, Kwon H, Lee J, Jang D, Pak Y. Insulin-response epigenetic activation of
Egr-1 and JunB genes at the nuclear periphery by A-type lamin-associated pY19-
Caveolin-2 in the inner nuclear membrane. Nucleic Acids Res 2015;43(6):3114–
27.
[32] Liu J, Lee KK, Segura-Totten M, Neufeld E, Wilson KL, Gruenbaum Y. MAN1 and
emerin have overlapping function(s) essential for chromosome segregation and
cell division in caenorhabditis elegans. Proc Natl Acad Sci U S A 2003;100
(8):4598–603.
[33] Mattioli E, Columbaro M, Jafferali MH, Schena E, Hallberg E, Lattanzi G. Samp1 mis-
localization in Emery-Dreifuss muscular dystrophy. Cells 2018;7(10).
[34] Broers JL, Kuijpers HJ, Ostlund C, Worman HJ, Endert J, Ramaekers FC. Both lamin
A and lamin C mutations cause lamina instability as well as loss of internal
nuclear lamin organization. Exp Cell Res 2005;304(2):582–92.
[35] Lammerding J, Hsiao J, Schulze PC, Kozlov S, Stewart CL, Lee RT. Abnormal nuclear
shape and impaired mechanotransduction in emerin-deficient cells. J Cell Biol
2005;170(5):781–91.
[36] Rowat AC, Lammerding J, Ipsen JH. Mechanical properties of the cell nucleus and
the effect of emerin deficiency. Biophys J 2006;91(12):4649–64.
[37] Hakelien AM, Delbarre E, Gaustad KG, Buendia B, Collas P. Expression of the myo-
dystrophic R453Wmutation of lamin A in C2C12 myoblasts causes promoter-spe-
cific and global epigenetic defects. Exp Cell Res 2008;314(8):1869–80.
[38] Holaska JM, Wilson KL. An emerin "proteome": purification of distinct emerin-
containing complexes from HeLa cells suggests molecular basis for diverse roles
including gene regulation, mRNA splicing, signaling, mechanosensing, and
nuclear architecture. Biochemistry 2007;46(30):8897–908.
[39] Ziat E, Mamchaoui K, Beuvin M, Nelson I, Azibani F, Spuler S, et al. FHL1B interacts
with lamin A/C and emerin at the nuclear lamina and is misregulated in Emery-
Dreifuss muscular dystrophy. J Neuromuscul Dis 2016;3(4):497–510.
[40] Windpassinger C, Schoser B, Straub V, Hochmeister S, Noor A, Lohberger B, et al.
An X-linked myopathy with postural muscle atrophy and generalized hypertro-
phy, termed XMPMA, is caused by mutations in FHL1. Am J Hum Genet 2008;82
(1):88–99.
[41] Buch C, Lindberg R, Figueroa R, Gudise S, Onischenko E, Hallberg E. An integral
protein of the inner nuclear membrane localizes to the mitotic spindle in mam-
malian cells. J Cell Sci 2009;122(12):2100–7.
[42] Tao S, Yamazaki D, Komazaki S, Zhao C, Iida T, Kakizawa S, et al. Facilitated hyper-
polarization signaling in vascular smooth muscle-overexpressing TRIC-A chan-
nels. J Biol Chem 2013;288(22):15581–9.
